Sunday, November 3, 2024
Facebook Linkedin Twitter
HomeTagsAscletis Pharma

Ascletis Pharma

Biotechnology

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

PR Newswire -
Ascletis Pharma Inc. announces that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for...
Biotechnology

Ascletis Announces Dosing of 24 Healthy Subjects of the First 3 Cohorts

PR Newswire -
Ascletis Pharma Inc. announces dosing of 24 healthy subjects of the first 3 cohorts in multiple-dose escalation Phase I clinical trial of oral RNA-dependent...
Biotechnology

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1

PR Newswire -
Ascletis Pharma Inc. announces the completion of first patient dosing in the U.S. Phase I clinical trial of ASC61, an oral PD-L1 small molecule...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics

Load more
ReadMagazine © | All rights reserved |Contact Us | Privacy Policy| Become A Guest Writer | Advertise with Us